GlobeNewswire by notified

Novo Nordisk to expand R&D presence in greater Boston area


Bagsværd, Denmark, 2 March 2023 – Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of its largest R&D hubs outside of Denmark. This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s US-based research and development activities.  

Novo Nordisk anticipates adding more than 200 new jobs in the Boston area in 2023. Of these new positions, more than 150 will be lab-based and clinical development personnel in Lexington and Watertown and involved in data science, biology or chemistry research, and ribonucleic acid interference (RNAi) research and clinical development.   

“The Boston area is the leading center of biopharmaceutical innovation in the US. With more than 1,000 life science companies, world-renowned institutions at the forefront of scientific discovery, and leading academic institutions, the life sciences community in greater Boston has produced some of the world’s most innovative ideas in medicine,” said Marcus Schindler, PhD, executive vice president for Research & Early Development and chief scientific officer of Novo Nordisk. “With today’s announcement, we are committing to further expansion and to having a major life sciences presence in the Boston area, to support pipeline expansion into new modalities, with the ultimate goal of delivering new innovative medicines to people living with chronic diseases.”  

In 2022, Novo Nordisk began to convert a 100,000 square foot space, which includes a state-of-the art new lab, adjacent to its existing facilities in Lexington. This facility will house its RNAi research and development and oral formulation units. More than 80,000 square feet of existing lab and office space will be available for use by R&D groups co-locating in Lexington. 

With the establishment of greater Boston as Novo Nordisk’s principal R&D location in the US, the company will transfer its lab-based discovery activities from Seattle to other locations in the global R&D network and close the R&D facility in Indianapolis. This is expected to result in the elimination of approximately 20 positions in Indianapolis and approximately 80 positions in Seattle. Novo Nordisk will be extending to affected employees the opportunity to pursue open positions at other locations. Novo Nordisk will continue to have a presence in Seattle, with a focus on digital therapy, data science and artificial intelligence. The R&D site dedicated to manufacturing of stem cells and stem cell-based therapies will continue to be based in Fremont, California.  

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information, visit,Facebook, Twitter, LinkedIn and YouTube.

Contact for further information

Ambre Brown Morley
+45 3079 9289

Natalia Salomao Abrahao (US)
+1 848 304 1027

Daniel Muusmann Bohsen
+45 3075 2175

Jacob Martin Wiborg Rode
+45 3075 5956

David Heiberg Landsted
+45 3077 6915

Mark Joseph Root (US)
+1 848 213 3219


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Flagning af generalforsamlingsfuldmagter til bestyrelsen21.3.2023 15:11:18 CET | pressemeddelelse

Til Nasdaq OMX Copenhagen 21. marts 2023 Selskabsmeddelelse nr. 03/2023 Flagning af generalforsamlingsfuldmagter til bestyrelsen I henhold til bekendtgørelse nr. 1172 af 31. oktober 2017 om storaktionærer meddeles det, at der til brug for GrønlandsBANKENs generalforsamling den 28. marts 2023 har GrønlandsBANKENs bestyrelse modtaget blankostemmefuldmagter, som repræsenterer 31,38 procent af aktiekapitalens stemmerettigheder eller 564.804 stk. aktier Den 28. marts 2023, når den ordinære generalforsamling er afholdt, ophører bestyrelsens adgang til at stemme i henhold til de modtagne fuldmagter. Eventuelle henvendelser kan rettes til: GrønlandsBANKEN Martin Kviesgaard Bankdirektør Direkte telefon: +299 34 78 02 Vedhæftet fil 03.Flagning_blankofuldmagter

Announcement of the granting of Power of Attorney to the Board of Directors21.3.2023 15:11:18 CET | Press release

To Nasdaq OMX Copenhagen 21 March 2023 Company Announcement No 03/2023 Announcement of the granting of Power of Attorney to the Board of Directors Pursuant to announcement no 1172 of 31 October 2017 regarding Major Shareholders, The BANK of Greenland hereby announces, that the Board of Directors have received unqualified Powers of Attorney for use on The BANK of Greenland’s ordinary general meeting March 28, 2023, representing 31.38 percent of the company’s share capital, or 564,804 shares. 28 March 2023 upon termination of the ordinary general meeting, the right of the Board of Director’s to vote in accordance with the Powers of Attorney granted shall cease. For further information, please contact: The BANK of Greenland Martin Kviesgaard Managing Director Telephone: +299 34 78 02 E-mail: Attachment 03.Flying of flags_unqualified powers of attorney

New member proposed for election to the Board of Directors21.3.2023 14:38:36 CET | Press release

Company announcement no 6-2023 Copenhagen, March 21, 2023 New member proposed for election to the Board of Directors Konsolidator’s Board of Directors proposes that Peter Gath is elected as a new member of the Board of Directors at the company’s upcoming Annual General Meeting scheduled for 23 March 2023. Consequently, Konsolidator’s Board of Directors proposes that the company’s Board of Directors will consist of five members: the Chairman of the Board, Jesper Eigen Møller, and the members Thomas Aporta, Cecilia Hultén, Claus Jul Christiansen, and Peter Gath. Peter Gath enters the Board of Directors with over 20 years of experience as a partner from EY and KPMG. Peter is currently CFO of St. Jørgen Holding and holds multiple Board Member positions, incl. in the listed company Brødrene A & O Johansen A/S. As a Chartered Accountant with a background in audit and leadership, as well as an Adjunct Professor at Copenhagen Business School (CBS) and former Chairman of the Danish Institute of